Intentar ORO - Gratis

Understanding Virus and Viral Vaccine Development Using Multi Spectral Advanced Nano-Tracking Analyzer (NTA)

Express Pharma

|

October 2020

AS the world today faces one of the biggest pandemics in the form of COVID-19, a wide range of candidate vaccines based on potential tools like viral vectors or virus like particles (VLP’s) are under development with the aim of protecting us against the life-threatening disease.

- Dr Namrata Jain, Kanika Thakur, Dr Jeffrey Bodycomb, Dr Rajeev Gautam, Dr John Kiran Anthony

Understanding Virus and Viral Vaccine Development Using Multi Spectral Advanced Nano-Tracking Analyzer (NTA)

For vaccines, thermostability is the key to successful global immunization programs as it can have a significant impact on the continuous cold-chain maintenance logistics, as well as on the vaccine potency. The stability of such a vaccine comes under increasing regulatory scrutiny, due to its potential effect on immunogenicity and the difficulties involved in its characterisation.

In order to comprehensively characterise stability and aggregation of vaccines, this article demonstrates the advantages of Multispectral Advanced Nanoparticle Tracking Analyser (ViewSizer™ 3000) from HORIBA Scientific. The ViewSizer 3000 can be used to understand the insights of particle sizing and viral titer [1] in the range of 10 nm to 15 μm. The combined capabilities of particle visualization, particle size and concentration measurements enable unmatched characterization and real-time monitoring of common kinetic processes such as dissolution of active pharmaceutical ingredients, self-assembly of polymers, crystallization of food and pharmaceutical products, aggregation of proteins, and particle agglomeration.

Vaccine Development

The ViewSizer 3000 can assist manufacturers to optimize the product shelf-life by evaluating the degree and the rate of aggregate formation in virus or VLP’s preparation through an immediate and direct estimation of product purity and concentration. As the technology also allows particle visualization and sizing, additional nanoparticle quantification is made available in a very short time when compared to conventional Plague Assays (PA) technique. For example, Figure 2

MÁS HISTORIAS DE Express Pharma

Express Pharma

Express Pharma

Speed and flexibility play a critical role in how we compete with larger global players

Kriti Jajoo, VP-BD and Strategy, Shriji Polymers, as the next-gen leader, speaks on how the company is evolving with a leadership approach that balances technology, sustainability, and customer-centricity to create long-term value, in an interview with Express Pharma

time to read

6 mins

January 2026

Express Pharma

Express Pharma

Vizag rising: Shaping India's pharma future

At the Vizag Pharma Summit 2025, hosted by Express Pharma, industry leaders discussed how quality, R&D, compliance, and emerging technologies are driving India's next phase of pharma growth

time to read

9 mins

January 2026

Express Pharma

Express Pharma

Future of pharma: Trends, challenges & AI

Industry experts discussed how Al is transforming pharmaceutical R&D, highlighting both the promise and the practical limitations of current technologies

time to read

2 mins

January 2026

Express Pharma

Express Pharma

Gandhi Automations presents multi-composites, high-performance door PRIME NEO for clean environments

When it comes to pharmaceutical facilities and laboratories, clean rooms' hygiene and protection from environmental contamination are the most important factors to consider.

time to read

1 mins

January 2026

Express Pharma

Express Pharma

Can Indian biosimilars and generics restate accessibility in global underserved markets?

Hari Kiran Chereddi, MD & CEO - HRV Pharma & NHG Pharma highlights that India's success in generics is no longer enough, as the world now demands advanced biologics, biosimilars, and personalised medicines. He further emphasises on the need for stronger regulation, innovation, and investment so India can lead in next-generation therapies and expand global access to cutting-edge healthcare

time to read

3 mins

January 2026

Express Pharma

Express Pharma

The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers

As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening formulation R&D, building a skilled and adaptable workforce, and closing gaps between academic research and industry needs.

time to read

6 mins

January 2026

Express Pharma

Express Pharma

Results win customers. Leadership discipline keeps them

Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.

time to read

3 mins

January 2026

Express Pharma

Express Pharma

INDIA'S INNOVATION JOURNEY FROM PROMISE TO PROOF

India's pharma ecosystem is ready to embrace stronger science and bolder ideas. Turning early breakthroughs into scalable, sustainable innovation remains the challenge

time to read

8 mins

January 2026

Express Pharma

Express Pharma

PRUV® -The original Sodium Stearyl Fumarate

JRS Pharma's PRUV® is the original sodium stearyl fumarate (SSF) introduced in the market over 20 years ago

time to read

5 mins

January 2026

Express Pharma

Express Pharma

Odisha's pharma pitch

The inaugural Odisha Pharma Summit 2025 delivered strong early signals of intent, positioning the state as an upcoming destination for PLI-triggered expansions, to complement existing pharma hubs. As Hemant Sharma, ACS Industry Dept and I&PR Dept, Govt of Odisha puts it, the aim is to “become a good, viable second option.” How fast can the eastern newcomer catch up and become India's next life sciences hub, asks Viveka Roychowdhury

time to read

5 mins

January 2026

Translate

Share

-
+

Change font size